Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jun 2024 | From Akero Therapeutics

Efruxifermin treatment improved collagen biomarkers consistent with remodelling of the extracellular matrix in patients with F2-F3 fibrosis due to MASH

Erik J Tillman, Doreen C Chan, Reshma Shringarpure, Diana J Leeming, Morten A Karsdal, Stephen A Harrison, Andrew Cheng, Kitty Yale, Tim Rolph 2024 International Liver Congress (EASL)

Jun 2024 | From Akero Therapeutics

LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)

Vlad Ratziu 2024 International Liver Congress (EASL)

May 2024 | From Akero Therapeutics

FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond

Stephen A. Harrison, Tim Rolph, Maddie Knot, Julie Dubourg Journal of Hepatology

Mar 2024 | From Akero Therapeutics

Efruxifermin significantly improved collagen biomarkers, consistent with beneficial ECM remodeling in patients with F2-F3 fibrosis due to MASH

Erik J Tillman, Doreen C Chan, Reshma Shringarpure, Diana J Leeming, Morten A Karsdal, Andrew Cheng, Kitty Yale, Tim Rolph Keystone Symposium MASH AND FIBROSIS: From Molecular Phenotypes to Precision Therapeutics

Mar 2024 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study

Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Timothy Rolph, Andrew Cheng, Kitty Yale Clinical Gastroenterology and Hepatology

Feb 2024 | From Akero Therapeutics

Decreases in liver cT1 accurately reflect histological improvement induced by therapies in MASH: a multi-centre pooled cohort analysis

Naim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, Anneli Andersson, Kitty Yale, Timothy Rolph, Raymund Chung, Raj K Vuppalanchi, Kenneth Cusi, Rohit Loomba, Andrea Dennis, Michele Pansini medRxiv, the preprint server for Health Sciences

Nov 2023 | From Akero Therapeutics

Efruxifermin in Compensated Cirrhosis due to NASH/MASH: Results from a Randomized, Double-blind, Placebo-controlled, Phase 2b Trial (SYMMETRY)

Stephen A. Harrison The Liver Meeting 2023 (AASLD)

Nov 2023 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist (GLP-1RA) in Patients with NASH/MASH and T2D: a Randomized, Placebo-controlled Study (Cohort D)

Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Tim Rolph, Andrew Cheng, Kitty Yale The Liver Meeting 2023 (AASLD)

We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline

We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline